Tip:
Highlight text to annotate it
X
No one likes needles.
And so if you can spare
patients the needle in drug
delivery, your company will
perhaps have a successful product. Particularly
in needle-free delivery, there's strong
and promising revenue growth and,
coming along with that, a
host of competitors and possible new entrance. These
systems are particularly useful
for the elderly and
the age of the population is
driving sales of new ways
to deliver vaccines particularly
but also other medications.
Can we do it, avoiding a
needle that, particularly with a
patient, an elderly patient, that
is going to see a lot
of injections, one after another,
eventually that's going to take its toll.
And so, clever pharmaceutical companies,
with their device partners, are finding
ways to develop these systems and
our report identifies those efforts,
how much opportunity there is out there for new entrance,
and what it will look like in the next five years.
An important consideration that
we found in this market that's
driving it, is the
desire of pharmaceutical companies
to get more patent life
out of their product.
Sometimes, if you can
figure out a way to
deliver a drug differently, you
can extend patent protection.
And many clever pharmaceutical companies have engaged in this strategy.
We talk about some of
those approaches in Kalorama
Information's report.
We break out the market
for systems by product type.
So, we'll have needle free and
we'll have those that are delivering
drugs through an implant,
sometimes on the patient's arm
or elsewhere, that delivers a drug slowly into the patient's
blood system or tissues.
We also delineate the market
in terms of the drug
products, and the device-
only revenue coming from that drug product.
You might be a device
company that's interested in
partnering with a pharma
company, but do not
have a drug product that's licensed
for you to manufacture on your own.
You want to find partners.
Our report can help, and it
can also give you a
reasonable estimate of the opportunity that
you may face in the next five years.
Watch biologics and watch
vaccines. It's very
common for vaccines to be
delivered through needle-free
delivery mechanisms, and one
of the great things about some of
these needle-free systems is that they're work horses.
You can do in some cases
as a provider a hundred and fifty patients a day with them.
And so they're very good for
vaccines because providers, retail
outlets, government agencies are
seeing a lot of adults
and children coming to their
door for vaccines now, particularly
the influenza vaccine.
And not everyone wants
that delivered through a needle quite
obviously, so devices that can
spare the patient that are
going to be an interesting trend to watch.
A particular challenge for
this market, and one that
companies will need to
address that we found in
our analysis is the cost of these systems.
They cost more than standard
injections, and so the
industry has to do a
better job of reducing that cost
per injection, to make it
beneficial to healthcare providers.
That's something that, if it
happens, and if the technology
can get there, and if
the manufacturers can make it
cheaper, that will see
explosive growth again in this market.